Proteasome inhibition: a novel approach to cancer therapy

被引：147

作者：

Adams, J ^{[1
]}

机构：

[1] Millennium Pharmaceut 75 Sidney St, Cambridge, MA 02139 USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2002年 / 8卷 / 04期

关键词：

D O I：

10.1016/S1471-4914(02)02315-8

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The central role of the proteasome in controlling the expression of regulators of cell proliferation and survival has led to interest in developing proteasome inhibitors as novel anticancer agents. In vitro and in vivo studies have shown that proteasome inhibitors have activity against a variety of tumor types. One of these agents, PS-341, has been tested in phase I trials in a variety of tumor types; in these trials, PS-341 treatment was well tolerated and preliminary evidence of biological activity was observed in some patients. Phase II trials in several hematological malignancies and solid tumor types are now in progress.

引用

页码：S49 / S54

页数：6